- Home
- BATL vs LSTA Comparison
BATL vs LSTA Comparison
Compare BATL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- LSTA
- Stock Information
- Founded
- BATL 1987
- LSTA 1980
- Country
- BATL United States
- LSTA United States
- Employees
- BATL N/A
- LSTA N/A
- Industry
- BATL Oil & Gas Production
- LSTA Misc Health and Biotechnology Services
- Sector
- BATL Energy
- LSTA Health Care
- Exchange
- BATL Nasdaq
- LSTA Nasdaq
- Market Cap
- BATL 21.7M
- LSTA 25.1M
- IPO Year
- BATL N/A
- LSTA N/A
- Fundamental
- Price
- BATL $1.13
- LSTA $2.53
- Analyst Decision
- BATL
- LSTA Strong Buy
- Analyst Count
- BATL 0
- LSTA 2
- Target Price
- BATL N/A
- LSTA $23.50
- AVG Volume (30 Days)
- BATL 53.1K
- LSTA 33.8K
- Earning Date
- BATL 08-14-2025
- LSTA 08-07-2025
- Dividend Yield
- BATL N/A
- LSTA N/A
- EPS Growth
- BATL N/A
- LSTA N/A
- EPS
- BATL N/A
- LSTA N/A
- Revenue
- BATL $185,206,000.00
- LSTA $1,070,000.00
- Revenue This Year
- BATL N/A
- LSTA N/A
- Revenue Next Year
- BATL N/A
- LSTA N/A
- P/E Ratio
- BATL N/A
- LSTA N/A
- Revenue Growth
- BATL N/A
- LSTA N/A
- 52 Week Low
- BATL $1.05
- LSTA $1.87
- 52 Week High
- BATL $6.89
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- BATL 35.05
- LSTA 45.71
- Support Level
- BATL $1.25
- LSTA $2.55
- Resistance Level
- BATL $1.31
- LSTA $2.87
- Average True Range (ATR)
- BATL 0.07
- LSTA 0.20
- MACD
- BATL -0.01
- LSTA -0.02
- Stochastic Oscillator
- BATL 9.09
- LSTA 12.70
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.